Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Aim(s): To assess the long-term effect of Lanreotide Autogel on the management of patients with malignant carcinoid syndrome.
Materials and methods: Seventy-five patients with midgut neuroendocrine tumors (NETs) referred to our tertiary referral centre were treated by deep subcutaneous injection with Lanreotide Autogel. Their case records were reviewed retrospectively. Clinical evaluation was based on symptom score and radiological assessment based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria at intervals of three to six months after commencement of treatment.
Conference: 7th Annual ENETSConcerence (2010)
To read the full abstract, please log into your ENETS Member account.